The accuracy of warfarin dosage based on VKORC1 and CYP2C9 phenotypes in a Chinese population

Agustinus Wijaya; Jiang T. Bo; He Jun; Jiang W. Ping; Jiang Bin; Chen H. Jie; Yang B. Wen; Xu M. Zhu; Qiu Q. Cheng

doi:10.13181/mji.v21i2.489

The accuracy of warfarin dosage based on VKORC1 and CYP2C9 phenotypes in a Chinese population

Authors

Agustinus Wijaya
Jiang T. Bo
He Jun
Jiang W. Ping
Jiang Bin
Chen H. Jie
Yang B. Wen
Xu M. Zhu
Qiu Q. Cheng

DOI:

https://doi.org/10.13181/mji.v21i2.489

Keywords:

CYP2C9, pharmacogenetic algorithm, VKORC1, warfarin

Abstract

Background: The aim of this study is to assess the accuracy of warfarin dosage based on VKORC1 and CYP2C9 genotype in Chinese population.

Methods: Blood samples were taken from 37 patients. We compared the warfarin dosage obtained from genotype (according to www.warfarindosing.org) and treatment dosage with international normalized ratio (INR) value within 2.0-3.0.

Results: The majority of Chinese people in our study are VKORC1 homozygous AA (89.2%), rarely VKORC1 heterozygous AG and we cannot find a patient with homozygous GG. For CYP2C9 genotype, most patients have the wildtype variants (CYP2C9*2 CC and CYP2C9*3 AA). The warfarin dosage for patients with VKORC1 AA and CYP2C9*3 AC is lower than for patients with other genotype variants.

Conclusion: There is no significant difference between pharmacogenetic algorithm (www.warfarindosing.org) and our treatment dosage. Our conclusion is that the pharmacogenetic algorithm is accurate to predict the warfarin dose. (Med J Indones. 2012;21:108-12)

Downloads

Download data is not yet available.

Downloads

Published

2012-05-01

How to Cite

Wijaya A, Bo JT, Jun H, Ping JW, Bin J, Jie CH, Wen YB, Zhu XM, Cheng QQ. The accuracy of warfarin dosage based on VKORC1 and CYP2C9 phenotypes in a Chinese population. Med J Indones [Internet]. 2012May1 [cited 2024Nov.21];21(2):108-12. Available from: https://mji.ui.ac.id/journal/index.php/mji/article/view/489

Download Citation

Issue

Vol. 21 No. 2 (2012): May

Section

Clinical Research

License

Authors who publish with Medical Journal of Indonesia agree to the following terms:

Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.